SCHEMBL10128205

SCHEMBL10128205

CC(C)S(=O)(=O)c1ccccc1Nc1nc(NCC2(N)CCCCC2)[nH]c(=O)c1C(N)=O

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 9/20 0.39
INSR P06213 3/20 0.39
ADRA2A P08913 1/20 0.37
ADRA1D P25100 1/20 0.37
ADRA1A P35348 1/20 0.37
ADRA1B P35368 1/20 0.37
CDK7 P50613 10/20 0.37
CDK9 P50750 10/20 0.37
AURKA O14965 1/20 0.37
NTRK1 P04629 1/20 0.37
IGF1R P08069 1/20 0.37
CDK4 P11802 1/20 0.37
EPHA1 P21709 1/20 0.37
CDK2 P24941 1/20 0.37
CDK3 Q00526 1/20 0.37
CDK6 Q00534 1/20 0.37
CDK5 Q00535 1/20 0.37
MET P08581 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10128146 1.00 ALK (0.39) ALKINSRADRA2AADRA1DADRA1A
SCHEMBL10128144 0.99 ALK (0.40) ALKINSRADRA2AADRA1DADRA1A
SCHEMBL282380 0.90 ADRA2A (0.38) ALKINSRADRA2AADRA1DADRA1A
SCHEMBL10128253 0.90 SYK (0.34) ALKINSR
SCHEMBL10128249 0.90 SYK (0.34) ALKINSR
SCHEMBL10128122 0.89 ADRA2A (0.38) ALKINSRADRA2AADRA1DADRA1A
SCHEMBL10128123 0.88 ADRA2A (0.38) ALKINSRADRA2AADRA1DADRA1A
SCHEMBL10128134 0.84 ALK (0.37) ALKINSRADRA2AADRA1DADRA1A
SCHEMBL10128128 0.84 PTK2 (0.37) ALKINSRADRA2AADRA1DADRA1A
SCHEMBL10128309 0.84 SYK (0.38) ALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 ALK 2/4885INSR 2024/4885ADRA2A 4375/4885
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 ALK 2/4885INSR 2024/4885ADRA2A 4375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.